The Oncology Institute's Q2 revenue up 21.5%, beats estimates

Oncology Institute

13/08/2025 21:14

Overview

Oncology Institute Q2 revenue rises 21.5% yr/yr, beating analyst expectations, per LSEG data

Adjusted EBITDA improves to $(4.1) mln from $(8.7) mln in prior year

Co's revenue growth driven by 40% increase in pharmacy business and new capitated lives

Outlook

Oncology Institute reaffirms 2025 revenue guidance of $460 to $480 mln

Company expects 2025 gross profit between $73 mln and $82 mln

Oncology Institute anticipates Q3 2025 adjusted EBITDA of $(2.5) to $(3.5) mln

Result Drivers

PHARMACY GROWTH - Pharmacy business grew over 40% year-over-year, driving revenue increase, according to CEO Daniel Virnich

CAPITATED LIVES - Addition of over 50,000 new capitated lives boosted value-based business revenue

GEOGRAPHIC EXPANSION - Ongoing expansion into new Florida regions with a major health plan expected to double covered lives for that payor

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$119.80 mln
$114.60 mln (2 Analysts)
Q2 Net Income
-$17 mln
Q2 Gross Profit
$17.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Oncology Institute Inc is $7.00, about 41.3% above its August 12 closing price of $4.11

Press Release: ID:nGNXBXC0C

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)